Prognostic impact of race and ethnicity in the treatment of colorectal cancer

Medical Clinics of North America

Volumn 89, Issue 5, 2005, Pages 1045-1057

  Mitchell, Edith P ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; CETUXIMAB; DIPEPTIDYL CARBOXYPEPTIDASE; DIURETIC AGENT; EPIDERMAL GROWTH FACTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PROTEIN TYROSINE KINASE INHIBITOR; VATALANIB;

ALOPECIA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; ETHNOLOGY; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSION; LIVER METASTASIS; META ANALYSIS; METASTASIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; RACE; REVIEW; STOMATITIS; TREATMENT OUTCOME;

AFRICAN AMERICANS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; SEER PROGRAM; SURVIVAL RATE; UNITED STATES;

EID: 24044552670     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2005.05.007     Document Type: Review

References (48)

1. L.A. Ries, M.P. Eisner, and C.L. Kosary SEER Cancer Statistics Review, 1973-1998 2001 National Cancer Institute Bethesda (MD)
2. S.L. Parker, K.J. Davis, and P.A. Wingo Cancer statistics by race and ethnicity [abstract] CA Cancer J Clin 48 1998 31 48
3. L.M. Axtel, and M.H. Myers Contrasts in survival of black and white cancer patients, 1960-1973 J Natl Cancer Inst 60 1978 1209 1215
4. J.L. Young, L.G. Ries, and E.S. Pollack Cancer patient survival among ethnic groups in the United States J Natl Cancer Inst 3 1984 341 352
5. P.A. Wingo, L.A. Ries, and S.L. Parker Long-term cancer patient survival in the United States [abstract] Cancer Epidemiol Biomarkers Prev 7 1998 271 282
6. V.W. Chen, C.M. Fenoglio-Preiser, and X.c. Wu Aggressiveness of colon carcionoma in blacks and whites. National Cancer Institute Black/White Cancer Survival Study Group [abstract] Cancer Epidemiol Biomarkers Prev 6 1997 1087 1093
7. R.Y. Demers, R.K. Serverson, and D. Schottenfeld Incidence of colorectal adenocarcinoma by anatomic subsite. An epidemiologic study of time trends and racial differences in the Detroit, Michigan area Cancer 79 1997 441 447
8. R.W. Beart, G.D. Steele Jr., and H.R. Menck Management and survival of patients with adenocarcinoma of the colon and rectum: a national survey of the Commission on Cancer J Am Coll Surg 181 1995 225 236
9. H. Daya, L. Polissar, and C.T. Yang Race, socioeconomic status, and other prognostic factors for survival from colorectal cancer J Chronic Dis 40 1987 857 864
10. G.S. Cooper, Z. Yuan, and A.A. Rimm Racial disparity in the incidence and case-fatality of colorectal cancer: analysis of 329 United States counties [abstract] Cancer Epidemiol Biomarkers Prev 6 1997 283 295
11. R.M. Mayberry, R.J. Coates, and H.A. Hill Determinants of black/white differences in colon cancer survival [abstract] J Natl Cancer Instit 87 1995 1686 1693
12. J.J. Dignam, Y. Ye, and L. Colangelo Prognosis after rectal cancer in blacks and whites participating in adjuvant therapy randomized trials J Clin Oncol 21 3 2003 413 420
13. L.A. Ries, P.A. Wingo, and D.S. Miller The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer Cancer 88 2000 2398 2424
14. A.D. McCollum, P.J. Catalano, and D.B. Haller Outcomes and toxicity in African-American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer [abstract] J Natl Cancer Inst 94 2002 1160 1167
15. P. Piedbois, and S. Michiels Survival benefit of 5FU/LV over 5FU bolus in patients with advanced colorectal cancer: an updated meta-analysis based on 2,751 patients [abstract 1180] Proc Am Soc Clin Oncol 22 2003 294
16. Meta-Analysis Group in Cancer Efficacy of intravenous continuous infusion of fluorouacil compared with bolus administration in advanced colorectal cancer J Clin Oncol 16 1998 301 308
17. J.A. Conti, N.E. Kemeny, and L.B. Saltz Irinotecan is an active agent in untreated patients with metastatic colorectal cancer J Clin Oncol 14 1996 709 715
18. H.C. Pitot, D.B. Wender, and M.J. O'Connell Phase II trial of irinotecan in patients with metastatic colorectal carcinoma J Clin Oncol 15 1997 2910 2919
19. P. Rougier, R. Bugat, and J.Y. Douillard Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy J Clin Oncol 15 1997 251 260
20. L.B. Saltz, J.V. Cox, and C. Blanke Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343 2000 905 914
21. J.Y. Douillard, D. Cunningham, and A.D. Roth Irinotecan combined with fluorouracil compared with fluorouracil along as first line treatment for metastatic colorectal cancer: a multicentre randomized trial Lancet 355 2000 1041 1047
22. Roche Laboratories, Inc Xeloda complete product information 2003 Roche Laboratories Nutley (NJ)
23. P.M. Hoff, R. Ansari, and G. Batist Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as fist line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study J Clin Oncol 19 2001 2282 2292
24. C. Tournigand, C. Louvet, and E. Puinaux FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): final results of a phase III study [abstract 494] Proc Am Soc Clin Oncol 2001 21
25. A. de Gramont, A. Figer, and M. Seymour Leucovorin and fluorouracil with or without oxaliplatin as firstline treatment in advanced colorectal cancer J Clin Oncol 18 2000 2938 2947
26. R. Goldberg, D.J. Sargent, and R.F. Morton A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 2004 23 30
27. C. Tournigand, T. Andre, and E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2004 229 237
28. Douillard JY. The new generation of CRC therapy: extending survival and the continuum of care [abstract]. Academy for Healthcare Education's The GI Cancer Challenge: Establishing Treatment Strategies Within the Evolving Paradigm Symposium conducted at the American Society of Clinical Oncology 40th Annual Meeting. New Orleans, Louisiana, June 5-8, 2004.
29. E. Van Cutsem, C. Twelves, and J. Taberno XELOX: mature results of a multinational, phase II trial of capecitabine plus oxaliplatin, an effective 1st line option for patients with metastatic colorectal cancer [abstract] Proc Am Soc Clin Oncol 22 2003 255 [Abstract 1023.]
30. Y.Z. Patt, E. Lin, and J. Leibmann Capecitabine plus irinotecan for chemotherapy-naïve patients with metastatic colorectal cancer (MCRC): US multicenter phase II trial [abstract] Proc Am Soc Clin Oncol 22 2003 281 [Abstract 1130.]
31. A. Grothey, K. Jordan, and O. Kellner Randomized phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin. (CapOx) as first line therapy of advanced colorectal cancer [abstract 1022] Proc Am Soc Clin Oncol 22 2003 255
32. A. Grothey, K. Jordan, and O. Kellner Capecitabine/irinotecan (CapeIri) and capecitabine/oxaliplatin (CapeOx) are active second line protocols in patients with advanced colorectal cancer (ACRC) after failure of first line combination therapy: results of a randomized phase II study [abstract 3534] Proc Am Soc Clin Oncol 23 2004 254
33. A.D. Roth, Y. Seium, and T. Ruhstaller Oxaliplatin combined with irinotecan (CPT-11) and 5FU/leucovorin in metastatic colorectal cancer: a phase I-II study [abstract 570] Proc Am Soc Clin Oncol 21 2002 143a
34. P. Carmeliet, and R.K. Jain Angiogenesis in cancer and other diseases Nature 407 2000 249 257
35. F. Kabbinavar, H.I. Hurwitz, and L. Fehrenbacher Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patient with metastatic colorectal cancer J Clin Oncol 21 2003 60 65
36. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
37. B. Morgan, A.L. Thomas, and J. Drevs Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies J Clin Oncol 21 2003 3955 3964
38. P.M. Harari, and S.M. Huang Modulation of molecular targets to enhance radiation Clin Cancer Res 6 2000 323 325
39. D. Cunningham, Y. Humblet, and S. Siena Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan refractory metastastatic colorectal cancer [abstract 1012] Proc Am Soc Clin Oncol 22 2003 252
40. D. Cunningham, S. Pyrhonen, and R.D. James Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer Lancet 352 1998 1413 1418
41. M.L. Rothenberg, A.M. Oza, and B. Burger Final results of a phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU, and leucovorin [abstract 1011] Proc Am Soc Clin Oncol 22 2003 252
42. S.S. Yoon, and K.K. Tanabe Surgical treatment and other regional treatments for colorectal cancer liver metastases Oncologist 4 1999 197 208
43. R. Adam, G. Pascal, and D. Castaing Liver resection for multiple colorectal metastases: Influence of preoperative chemotherapy [abstract 1188] Proc Am Soc Clin Oncol 22 2003 296
44. S.R. Alberts, J.H. Donohue, and M.R. Mahoney Liver resection after 5-fluorouracil, leucovorin and oxaliplatin for patients with metastatic colorectal cancer limited to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study [abstract 1053] Proc Am Soc Clin Oncol 22 2003 263
45. S. Gill, C.L. Loprinzi, and D.J. Sargent Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22 2004 1797 1806
46. M.J. O'Connell Current status of adjuvant therapy for colorectal cancer Oncology 18 2004 751 755
47. Giacchetti. 2000.
48. Grothey. 2002.